Amid strategic pivot, 2seventy bio plots comeback for BMS-partnered CAR-T Abecma
Fierce Pharma
JANUARY 30, 2024
2seventy Bio has traveled a difficult path ever since it spun out from bluebird bio to work on cancer cell therapies. | 2seventy Bio has traveled a difficult path ever since it spun out from bluebird bio to work on cancer cell therapies. Now, the company is splitting in two once again, passing its R&D programs to Regeneron and going all-in on its Bristol Myers Squibb-partnered CAR-T Abecma.
Let's personalize your content